Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 10/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 10/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 10/20 | 0.44 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.43 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3436653 | 0.84 | HDAC1 (0.50) | HDAC1HDAC8HDAC6TBXA2RTBXAS1 | |
| SCHEMBL3436645 | 0.82 | HDAC1 (0.65) | HDAC1HDAC8HDAC6TBXA2RTBXAS1 | |
| SCHEMBL21137838 | 0.81 | HDAC1 (0.40) | HDAC1HDAC8HDAC6TBXA2RTBXAS1 | |
| SCHEMBL3436661 | 0.81 | HDAC1 (0.44) | HDAC1HDAC8HDAC6TBXA2RTBXAS1 | |
| SCHEMBL3436662 | 0.76 | HDAC1 (0.45) | HDAC1HDAC8HDAC6TBXA2RTBXAS1 | |
| SCHEMBL3554151 | 0.76 | HDAC1 (0.46) | HDAC1HDAC8HDAC6ALDH1A1 | |
| SCHEMBL3436664 | 0.75 | IRAK4 (0.48) | — | |
| SCHEMBL3436665 | 0.75 | IRAK4 (0.46) | HDAC1HDAC8HDAC6TP53NPC1 | |
| SCHEMBL2304408 | 0.75 | POLB (0.47) | HDAC1HDAC8HDAC6TBXA2RTP53 | |
| SCHEMBL162560 | 0.75 | NPC1 (0.46) | TBXA2RTP53NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | HDAC1 372/4885HDAC8 384/4885HDAC6 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.